Aspira Women’s Health 

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aspira Women's Health (AWH) sees robust growth and innovation in Q1 2024

Aspira Women's Health (AWH) reported strong performance in Q1 2024, driven by significant growth in test volumes and improvements in financial metrics. The company's focus on innovation and collaboration underscores its commitment to advancing women's health diagnostics. While challenges in funding persist, AWH's strategic initiatives and market opportunities position it for continued growth and success in the future.

Aspira Women's Health achieves record test volumes amidst cost challenges

AWH reported strong performance in test volumes and revenue growth in Q2 2024.
While facing challenges with margins and costs, the company is actively addressing them.
Opportunities lie in product development, market expansion, and cost control measures.
Overall, AWH is strategically positioned for growth and innovation in the women's health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid

Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript

2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023. “We made a great deal of progress in 2023.

Aspira Women's Health Reports Fourth Quarter and Full Year 2023 Financial Results

AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.

Aspira Women's Health to Present at the MedInvest Biotech & Pharma Investor Conference

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024. Management will also host a conference call at 4:30 pm to discuss financial results and provide a corporate update. Details for the call are as follows:

Aspira Women's Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024

AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.

Aspira Women's Health to Present at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024.

Aspira Women's Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)

AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it will host a virtual R&D day featuring experts who will present the exciting progress of the company's product pipeline on January 4, 2024 at 11:00 AM ET. To register, click here.

Aspira Women's Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024

AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for partnering and institutional one-on-one meetings in San Francisco, during JP Morgan's Healthcare Conference Week 2024. Nicole Sandford, President and Chief Executive Officer, in addition to Torsten Hombeck, Ph.D., Chief Financial Officer from the management team will be in attendance at the following corporate access and partnering events:

Aspira Women's Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024

Data supports EndoCheck™  to be the first blood test for the identification of localized endometriosis, including endometrioma

Aspira Women's Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis

California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test

Aspira Women's Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)

CMS approves OvaWatch SM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1. Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024.

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2023 Earnings Call November 13, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Aspira Women's Health Incorporated Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Aspira Women's Health Inc. (AWH) Q3 2023 Earnings Call Transcript

The proposed rule would allow for OvaWatch SM to be reimbursed at the same rate as Ova1 ® at $897 per test and will become final following a brief public comment period

Aspira Women's Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch

Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests

Aspira Women's Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

The conference is taking place on October 5-6, 2023, in Los Angeles, CA The conference is taking place on October 5-6, 2023, in Los Angeles, CA

Aspira Women's Health to Present at the BioVenture Nexus Conference

Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year.

Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?

Aspira (AWH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Aspira (AWH) Rating Upgrade to Buy

Boxlight

Duos Technologies Group

Intuitive Machines Inc

Sirius XM Holdings Inc

Scotts Miracle-Gro

Sprout Social

While some publicly traded enterprises left no doubt as to their trajectory, a few others are just now benefiting from a late summer stock surge. Better late than never, though.

Eleventh-Hour Climbers: 7 Stocks Gearing Up for a Late Summer Surge

Samples to be used in validating the Company's EndoCheck SM test in development for the diagnosis of endometriosis

Aspira Women's Health Signs Exclusive Sample Procurement Agreement with The University of Oxford

AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women's health diagnostic tools for gynecologic diseases, today announced it has named Michelle Snider as Senior Vice President, Commercial Strategy and Operations.

Aspira Women's Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

Aspira Women's Health Inc. (NASDAQ:AWH ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Nicole Sandford – President and Chief Executive Officer Torsten Hombeck – Chief Financial Officer Conference Call Participants Sally Yanchus – Water Tower Research Andrew Brackmann – William Blair Operator Good afternoon, ladies and gentlemen, and welcome to Aspira's Women's Health, Incorporated Second Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.

Aspira Women's Health Inc. (AWH) Q2 2023 Earnings Call Transcript

Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022.

Aspira Women's Health® Reports Second Quarter 2023 Financial Results

AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Ryan Phan, Ph.D., is stepping down as the Company's Chief Scientific and Operating Officer effective September 15, 2023. Dr Phan is expected to remain as an advisor for the Company to provide scientific and operational advice related to ongoing product development programs.

Aspira Women's Health Announces Transition of its Chief Scientific Officer/Chief Operating Officer

AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will report its financial results for the three months ended June 30, 2023 on Monday, August 14, 2023. Management will host a conference call to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows:

News for Aspira Women’s Health Stock (AWH)